Cardioplegia Solution 122 mEq K Recalled for Sterility Failure
Central Admixture Pharmacy Services is recalling Cardioplegia Solution due to lack of sterility assurance and missing validation data for decontamination. The product was distributed nationwide.
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: This is an FDA Class II recall for a critical-use cardiac drug. No illnesses or injuries are reported in the source. Per the rubric, risk-of-harm products without reported injury score at 3 (High).
Plain-English summary
Central Admixture Pharmacy Services, Inc. is recalling Cardioplegia Solution 122 mEq K in 1000 mL IV bags. The recalled lot is 36-256332, expiring 7/29/2023. A total of 80 bags were distributed nationwide.
The FDA initiated this recall because the manufacturer lacks assurance of sterility and validation data for the decontamination cycles used to prepare the product. This creates a risk that the product may not be sterile.
Hospitals, surgical centers, and other healthcare facilities using this product should immediately stop use of the affected lot and contact Central Admixture Pharmacy Services or the FDA for guidance on replacement or alternatives.
The recalled product
- Product
- CARDIOPLEGIA SOLUTION 122 mEq K, Modified St. Thomas Formula High Potassium, Total Volume = 1000 mL, IV Bag, Rx only, Central Admixture Pharmacy Services, Inc., 2200 South 43rd Avenue, Pheonix, AZ 85043, NDC: 72196-0209-1
- Manufacturer
- Central Admixture Pharmacy Services, Inc.
- Category
- Drug — Cardiac / IV Solution
- Hazard
- lack-of-sterility
- missing-validation
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot:36-256332
- Exp. 7/29/2023.
Distribution
Distributed nationwide across the United States.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27